Group Profile
Chipscreen Biosciences is an innovative drug company driven by core technologies and globally competitive pipelines. As a leader in drug innovation & development in China,we adhere to the principle of "Constant Innovation for Life". We focus on developing groundbreaking drugs with new mechanisms of action, to meet the urgent clinical needs of patients. Our comprehensive industry chain that covers early exploratory discovery through commercialization allows us to provide innovative drugs for patients worldwide.
With a global development strategy based on early-stage research in China, Chipscreen Biosciences has leveraged the top scientists and teams with extensive experience in related fields from the Shenzhen Small Molecule Early R&D Center and Chengdu Small Molecule Early R&D Center to create an integrated technology platform based on AI-driven design and chemical genomics, which spanned the whole process from basic science to clinical translation. We have successfully developed first-in-class and best-in-class innovative drugs. Currently, we have marketed two drugs for three indications in Mainland China, two indications in Japan, and one indication in Taiwan, China. In addition, we have launched a number of R&D projects with differentiated advantages and global competitiveness in the five major areas, including malignant tumors, metabolic diseases, autoimmune diseases, central nervous system diseases, and antivirals.
Chipscreen Biosciences has formed a global industrial layout consisting of Shenzhen Head Office/R&D Center/GMP production base, Chengdu Regional Head Office/R&D Center/GMP production base, Beijing Branch, Shanghai Branch, and Chipscreen Biosciences (USA) Co., Ltd. Meanwhile, as one of the first batches of national "innovative drug incubation bases" and national high-tech enterprises, Chipscreen Biosciences has independently undertaken many national "863" plans and national major science and technology projects, such as "10th five-year plan", "11th five-year plan", "12th five-year plan" and "13th five-year plan", and National Science and Technology primary Project for Innovative Drug Development. We have filed over 700 invention patents in China and worldwide, with over 200 granted.
Shenzhen Chipscreen Pharmaceutical Ltd.
Shenzhen Chipscreen Pharmaceutical Ltd., incorporated on Mar. 16, 2017, is located at No. 21, Jinxiu East Road, Kengzi Street, Pingshan New District, Shenzhen. A wholly-owned subsidiary of Shenzhen Chipscreen Biosciences Co., Ltd., it was formerly the Pingshan manufacturing base of Chipscreen Biosciences, and is now the industrialization base for the Company’s first original anti-tumor drug, Chidamide. The subsidiary consists of the Group’s innovative drug CMC technology transfer center, an oncologic API and formulation workshop, a quality management center, and other production-related supporting facilities.
Chengdu Chipscreen Pharmaceutical Ltd.
Chengdu Chipscreen Pharmaceutical Ltd., incorporated on Apr. 28, 2014, is a wholly-owned subsidiary of Shenzhen Chipscreen Biosciences Co., Ltd. Consisting of two sites, the Innovative Drug Manufacturing Base and the Innovative Drug R&D Center and Regional Headquarters, Chengdu Chipscreen Pharmaceutical plays a pivotal role in the regional development of the Group.
The Innovative Drug Manufacturing：Base is located at No. 298, Kangqiang Yi Road, West High-tech Zone, Chengdu. The facilities here include oncology and non-oncology API and oral solid formulation workshops, which are designed in accordance with GMP standards of the US, EU and China. In order to fully meet demand for pilot scale testing of innovative drugs, preparation of clinical samples and production of commercial batches, new facilities including workshops for oncologic and non-oncologic injections and antibody drugs are under construction.
The Innovative Drug R&D Center and Regional Headquarters：is located at No. 18, Xintongnan Yi Road, Xinchuan Science and Technology Park, South High-tech Zone, Chengdu. A vital part of the Group’s R&D system, the Innovative Drug R&D Center will work with and complement the Early Research & Development Center (Shenzhen) in building product pipelines and supporting clinical research needed for the company’s sustainable development.
Beijing Branch of Shenzhen Chipscreen Biosciences Co., Ltd.,( Clinical Research Center of Shenzhen Chipscreen Biosciences Co., Ltd.,)
located in Chaoyang District, Beijing, is a Clinical Research and Operations Center, functioning as clinical project managements and supporting for drug registrations.
Shanghai Branch of Shenzhen Chipscreen Biosciences Co., Ltd., (Business Center of Shenzhen Chipscreen Biosciences Co., Ltd., )
located in Putuo District, Shanghai, is the Group’s marketing center, as well as the base for product strategy development and business expansion.
Chipscreen Biosciences (United States) Limited
Founded in April 2021 and headquartered in New Jersey, Chipscreen Biosciences (USA) Ltd. is a wholly owned subsidiary of Chipscreen Biosciences. It is committed to advancing the clinical development of the company’s innovative drugs globally. Upholding the motto “Constant Innovation for Life,” the U.S. subsidiary has built a U.S.-based R&D platform to accelerate the clinical translation and global registration of drug candidates, including CS231295. Leveraging its parent company’s strong AI-assisted design and chemical genomics platforms, the U.S. team works closely with early R&D forces in China and international multicenter clinical networks, forming a globalized drug development system. The company will continue to drive the global advancement of CS231295 and aims to bring breakthrough therapies to patients with brain tumors and other unmet medical needs.
Chengdu Chipscreen Newway Biosciences Co., Ltd.
Chengdu Chipscreen Newway Biosciences Co., Ltd. (hereinafter referred to as "Chipscreen Newway") is an innovative biotechnology enterprise committed to the development of large molecules and other novel therapeutic technologies. Chipscreen Newway specializes in novel therapeutic methods and technologies including but not limited to nucleic acid drugs and large molecules represented by antibodies and Antibody–Drug Conjugates (ADC). We are dedicated to developing drugs with novel mechanisms of action that meet clinical needs in disease areas, such as tumors and autoimmune diseases, to provide patients with innovative and leading therapeutic methods and options.
Pengzhou Chipscreen Pharmaceutical Ltd.
The third innovative drug production base of the group, with an area of about 100 mu (approximately 16.5 acres), will focus on the scale-up production of Chiglitazar Sodium and the production guarantee for future pipelines. The construction of the project has already started.
